Navigation Links
Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimer's Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
Date:4/16/2013

NEW YORK, April 16, 2013 /PRNewswire/ -- Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV meeting is the preeminent international conference in the rapidly growing field of exosome and microvesicle research.

"The ability to deliver full-length, high quality mRNA and microRNA from biofluids is critical to development of new research tools and clinical grade in vitro diagnostic tests not subject to the limitations of tissue biopsy," said Dr. Johan Skog , chief science officer of Exosome Diagnostics. "Our Alzheimer's disease findings are especially pertinent to advancing a molecular diagnostic test capable of detecting CNS disorders years before the onset of clinical symptoms when therapeutic intervention could provide the most benefit."

Dr. Skog will give two oral presentations. The first is entitled "Characterization of Exosome RNA as a Tool for Molecular Diagnostics", and will be given at 9:30 a.m. EDT on April 16 during the Frye Halloran Educational Symposium. The latest data on Exosome Diagnostics' proprietary biofluid RNA capture technology for disease biomarkers in urine, blood and cerebrospinal fluid (CSF) will be presented. The second, to be given at 9:45 a.m. EDT on April 20, is entitled "The Use Of CSF Microvesicle RNA For Diagnosis Of Alzheimer's Disease". This  presentation describes differences in CSF exosome microRNA expression associated with Alzheimer's disease and patients with subjective memory complaints but no evidence of Alzheimer's disease. 

James McCullough , chief executive officer of Exosome, said, "We are committed to enabling the research community with high-performance exosome technology RNA isolation kits beginning in 2014 for biomarker discovery from fresh and frozen biofluids.  In addition, we are continuing to advance multi-center in vitro diagnostic development programs in genitourinary (GU) Oncology and CSN disorders."  

Exosome Diagnostics' proprietary technology provides access to a previously unexplored source of genetic information directly from diseased cell populations.  Cells throughout the body shed exosomes into fluids as a natural package delivery system to other cells.  Exosomes carry key genes (mRNA and miRNA transcript) responsible for commanding disease growth that can be accessed quickly and repeatedly from a biofluid for analysis on PCR or next-generation sequencing instruments.  Exosome technology has the potential to allow doctors, researchers and drug developers to take repeated, accurate genetic "snapshots" of disease for diagnostic and therapeutic use without the need for a surgical tissue biopsy.

Exosome Diagnostics will also be presenting a poster on an additional study:

Abstract #37, 8-5:30pm EDT, Wednesday, April 17th:  Utility of Urinary Exosomes/Microvesicles to Non-Invasively Analyze Gene Expression in Prostate Cancer

L.M. Russo , A.N. Scott , P. Motamedinia, K.L. Bate , N. Sadeghi, G. Salazar, M. Lipsky, J. Lin, G. Hruby, K.K. Badani , D.P Petrylak, J.M McKiernan

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is commercializing exosome technology products for use in both the life sciences and clinical settings. For more information, please visit www.exosomedx.com.

Exosome Contact:
James McCullough
Chief Executive Officer
Exosome Diagnostics
(646) 843-4949

Exosome Media Contact:
Robert Flamm , Ph.D.
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
2. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
3. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
4. QBC Diagnostics Awarded GSA Contract
5. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
6. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
7. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
8. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
9. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
10. Breakthrough Prostate Cancer Diagnostics
11. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016   Change Healthcare , ... network solutions and technology-enabled services designed to ... into a strategic channel partnership with SourceMed, ... solutions and revenue cycle management services that ... rehabilitation clinics to optimize revenue, operational efficiency ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... There are many ways to cook a hot dog, but ... Americans prefer their dogs straight off the grill. Of the 90 percent of Americans ... to cook a hot dog, far outpacing other cooking methods such as steaming (12 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
(Date:5/26/2016)... ... , ... On Memorial Day, Hope For Heroes and USA Medical ... for the country. The nonprofit Hope For Heroes partnered with the leading provider ... for disabled military veterans, as well as police, firemen, and EMS professionals across the ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million people living ... survivors worldwide. On Sunday, June 5, 2016, communities around the world will gather to ... , National Cancer Survivors Day® is an annual worldwide Celebration of Life that ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel ... Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale ... of Retina Group of New York , is a Board Certified ophthalmologist ...
Breaking Medicine News(10 mins):